Cost and regulatory pressures, dependence on Asian supplies of active ingredients and the growing importance of drug sovereignty were the main topics of a meeting between Finance and Economy Minister Andrzej Domanski and representatives of the Polish pharmaceutical industry. The talks focused on the sector's challenges, but also on its strategic role for the country's health and economic security.
Meeting between the Minister of Finance and the Polish pharmaceutical industry
Published Jan. 12, 2026 08:15
Fot. Getty Images/iStockphoto
On January 9, 2026, Finance and Economy Minister Andrzej Domanski met with representatives of Poland's largest pharmaceutical industry organizations. The purpose of the talks was to exchange opinions on the current situation of the industry and to identify measures that could strengthen its stability and competitiveness.
Participants at the meeting agreed that the pharmaceutical sector across the European Union today faces mounting cost, regulatory and environmental pressures. Europe's heavy dependence on the supply of active ingredients and intermediates from Asia, which in recent years has highlighted the scale of the risk to the continuity of drug supplies, also remains a particular challenge.
Minister Andrzej Domanski stressed that from the government's perspective, pharmacy should be one of the foundations of modern industry in Poland - important both for public health and for the development of innovation, exports and the labor market. - Pharmacy today is not only an important industry. It is one of the pillars of state security, the resilience of the economy and the stability of the health care system. Drug sovereignty is becoming an element of national security, comparable to energy or food security," he said.
The meeting also highlighted the importance of the involvement of innovative pharmaceutical companies in the Polish economy, particularly through clinical trials. It was emphasized that the available infrastructure, regulatory environment and dynamic development of the domestic sector make Poland an attractive place for investment in the field of innovative pharma.
The pharmaceutical sector currently accounts for about 0.75 percent of the country's GDP, generating more than PLN 26 billion in gross value added. It also provides more than 80,000 jobs along the value chain. The value of production exceeds PLN 21 billion a year, an increase of about 45 percent over the past five years.
As emphasized during the talks, further strengthening the country's pharmaceutical capacity can be crucial not only for the development of the economy, but also for the resilience of the health system and the drug safety of patients.
Source: Ministry of Development and Technology
